SVB Leerink analyst David Risinger downgrades Regeneron Pharmaceuticals (NASDAQ:REGN) from Outperform to Market Perform and lowers the price target from $738 to $630.
Morgan Stanley analyst James Faucette downgrades Open Lending (NASDAQ:LPRO) from Equal-Weight to Underweight and lowers the price target from $14 to $8.
Morgan Stanley analyst Drew Ranieri initiates coverage on Integra Lifesciences (NASDAQ:IART) with a Equal-Weight rating and announces Price Target of $59.